Merck


Electronics came as a big surprise

15/05/24 -"Merck started the year well, with Electronics being the largest contributor, demonstrating organic sales growth after several stagnant quarters. Healthcare also posted robust top-line growth and even ..."

Pages
68
Language
English
Published on
15/05/24
You may also be interested by these reports :
09/06/26
Our estimates for 2026-2027 have been revised downward following the reclassification of Capsules & Health Ingredients (CHI) as discontinued ...

08/06/26
Anticipated sales are now even more skewed toward 2H, with HSD growth expected in 1H. We also record a CHF15m decrease in Building K sales in 2026, ...

04/06/26
Over the 5 days to 02-06, 18 pharma stocks out of the 23 under coverage fell. The sector performance chart is not looking good. We see an opportunity ...

01/06/26
At a time when a lot of Big Pharmas are losing sleep because of looming patent expirations over the next five years, the likes of Sandoz (REDUCE; ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO